|
|
News Breaks | | | | February 28, 2013 | | 16:07 EDT |  | CTIC | Cell Therapeutics sees FY13 loss from operations $60M-$65M
For 2013, loss from operations is expected to be approximately $60M-$65M, excluding non-cash stock-based compensation expense. The projected decrease in 2013 loss from operations, compared to 2012, primarily relates to expected changes in contribution margin from PIXUVRI commercial operations, as it intends to operate the commercial business with a net positive contribution; SG&A expenses, including sales and marketing expenses to drive sales of PIXUVRI; and R&D expenses. | |
|
News For CTIC From The Last 14 Days Check below for free stories on CTIC the last two weeks. |
|
|
| May 20, 2013 | | 05:47 EDT | | CTIC | Cell Therapeutics reports the G-BA issues final assessment report for Pixuvri
 Subscribe for More Information | |
|
|
|
|
|
|
